Spectrum Physician's Orders **Health** BELIMUMAB (BEN **BELIMUMAB (BENLYSTA) -ADULT, OUTPATIENT, INFUSION CENTER**

Patient Name
DOB
MRN
Physician
FIN

	Page 1 of 2				
Defaults for orders not otherwise specified below: INITIAL DOSES: Interval: Every 14 days x 3 treatments MAINTENANCE DOSES: Interval: Every 28 days					
Duration: ☐ Until date: ☐ 1 year ☐# of Treatmen					
Anticipated Infusion Date	ICD 10 Code with Des	scription			
Height(cn	n) Weight(kg) Allergies_				
Provider Specialty					
☐ Allergy/Immunology☐ Cardiology☐ Gastroenterology	☐ Infectious Disease☐ Internal Med/Family Practice☐ Nephrology	□ OB/GYN□ Other□ Otolaryngology	☐ Rheumatology☐ Surgery☐ Urology		
☐ Genetics Site of Service	□ Neurology	☐ Pulmonary	☐ Wound Care		
☐ SH Gerber☐ SH Helen DeVos (GR)	□ SH Lemmen Holton (GR)□ SH Ludington	□ SH Pennock□ SH Reed City	☐ SH United Memorial☐ SH Zeeland		
Appointment Requests					
	eted: S, Expires: S+365, Sched. Tolerance: Sche labs. Verify that all INDUCTION/LOADING DOS				
Safety Parameters and Spec	cial Instructions				
INSTRUCTIONS (RAMETERS AND SPECIAL 3 I/LOADING DOSES given prior to start of MAIN	TENANCE DOSES			
Nursing Orders					
ONC NURSING C BELIMUMAB (BENLY	COMMUNICATION 14 (STA):				
An FDA-approved patient medication guide, which is available with the product information and at http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125370s055lbl.pdf#page=21, must be dispensed with this medication.					
Monitor for hypersensitivity reactions; onset may occur within hours of the infusion or may be delayed. Non-acute hypersensitivity reactions, including facial edema, fatigue, headache, myalgia, nausea, and rash have been reported and may occur up to a week following infusion. Immediately discontinue infusion for severe reactions and contact provider.					
	OMMUNICATION 100 er Patency Adult Protocol				
Vitals					

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

Vital Signs

Routine, PRN, Starting S, Take vital signs at initiation and completion of infusion and as frequently as indicated by patient's symptoms

Spectrum BELIMUMAB (BENLYSTA) - **Health** ADULT, OUTPATIENT, **INFUSION CENTER** (CONTINUED) of 2

Patient Name
DOB
MRN
Physician
FINI

Pre-Medic	ations
~	acetaminophen (TYLENOL) tablet
	□ 325 mg
	□ 500 mg
	□ 650 mg
	□ 1000 mg
	Oral, Once, Starting S, For 1 Dose
~	diphenhydrAMINE (BENADRYL) capsule
_	□ 25 mg
	□ 50 mg
	Oral Once Starting C. For 1 Door
	Oral, Once, Starting S, For 1 Dose
	Pre-medication with dose:
Medicatio	ns
~	belimumab (BENLYSTA) 10 mg/kg in sodium chloride 0.9 % 250 mL IVPB
	10 mg/kg, Intravenous, Administer over 1 Hour, Once, Starting 30 minutes after treatment start time, For 1 Dose
	Discontinue infusion for severe hypersensitivity reaction (eg, anaphylaxis, angioedema). The infusion may be slowed or temporarily
	interrupted for minor reactions. Consider premedicating with an antihistamine and antipyretic for prophylaxis against hypersensitivity or infusion reactions.

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

 $Telephone\ order/Verbal\ order\ documented\ and\ read-back\ completed.\ \ Practitioner's\ initials\ _$

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:			
	TIME	DATE	TIME	DATE	TIME	DATE	Pager #
		Sign		R.N. Sign		Physician Print	Physician

EPIC VERSION DATE: 03/19/20